Pyxis Oncology (NASDAQ:PYXS) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Pyxis Oncology has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, signaling a shift in analyst sentiment regarding the stock.
• Despite the downgrade, four analysts still maintain a "buy" rating, with average price targets suggesting potential upside, currently set at $7.75.
• The company reported a loss of $0.30 per share last quarter, surpassing analysts' expectations, while revenue for the quarter was recorded at $2.82 million.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Friday.

A number of other equities analysts have also recently issued reports on the stock. Guggenheim started coverage on shares of Pyxis Oncology in a research report on Wednesday, September 3rd. They set a "buy" rating and a $5.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Tuesday, August 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pyxis Oncology in a report on Saturday, September 27th. Finally, Zacks Research upgraded shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pyxis Oncology currently has an average rating of "Hold" and an average price target of $7.75.

Pyxis Oncology Price Performance

PYXS traded up $0.32 during midday trading on Friday, reaching $2.57. 1,074,884 shares of the company's stock were exchanged, compared to its average volume of 820,668. The stock has a market capitalization of $159.39 million, a PE ratio of -1.61 and a beta of 1.33. The business's 50-day moving average price is $1.59 and its 200 day moving average price is $1.29. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $2.82 million for the quarter. As a group, analysts expect that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors have recently bought and sold shares of PYXS. Jane Street Group LLC purchased a new stake in Pyxis Oncology in the second quarter valued at approximately $370,000. Pier 88 Investment Partners LLC grew its holdings in Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock valued at $383,000 after purchasing an additional 292,370 shares during the period. Schulhoff & Co. Inc. grew its holdings in Pyxis Oncology by 125.4% in the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company's stock valued at $302,000 after purchasing an additional 153,000 shares during the period. Marshall Wace LLP purchased a new stake in Pyxis Oncology during the second quarter worth approximately $163,000. Finally, 683 Capital Management LLC grew its stake in Pyxis Oncology by 32.5% during the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock worth $539,000 after buying an additional 135,000 shares during the period. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.